Income Statement
ESTRELLA IMMUNOPHARMA, INC.
ESLA
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Jun 30, 2024 2024 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|
|
Revenue
|
- | - | - | - |
|
Cost of Revenue
|
- | - | - | - |
|
Gross Profit
|
- | - | - | - |
|
Operating Expenses
|
13.06 | 7.31 | 1.37 | 0.18 |
|
Research & Development
|
10.25 | 4.11 | - | - |
|
Selling, General & Administrative
|
2.81 | 3.20 | - | - |
|
Other Operating Expenses
|
- | - | - | - |
|
Operating Income
|
-13.06 | -7.31 | -1.37 | -0.18 |
|
Non-Operating Income
|
0.00 | 0.00 | -0.45 | 0.07 |
|
Interest Income
|
- | - | - | 0.00 |
|
Interest Expense
|
- | - | - | - |
|
Other Non-Op Income / Expense
|
- | - | - | - |
|
Income Before Tax
|
-13.06 | -7.31 | -0.92 | -0.25 |
|
Income Tax Expense
|
0.00 | 0.00 | -0.92 | -0.25 |
|
Non-Controlling Interest
|
- | - | - | - |
|
Net Income
|
-13.06 | 14.62 | 0.00 | 0.00 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Jun 30, 2024 2024 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - |
|
EBITDA
|
-13.06 | -7.31 | -1.37 | -0.18 |
|
Earnings Per Share (Basic)
|
-0.35 | -0.27 | -0.16 | 0.76 |
|
Diluted EPS
|
-0.35 | - | -0.16 | 0.76 |
|
Weighted Average Shares
|
36.82 | 27.10 | 4.34 | 2.03 |
|
Diluted Weighted Avg Shares
|
36.82 | - | 4.34 | 2.03 |
|
Comprehensive Income
|
- | - | - | - |